Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Byonyks Medical Devices Inc. focuses its patent efforts within the Chemistry & Materials technology area. The portfolio currently shows 1 pending office action. This single active matter suggests a targeted prosecution strategy for the company's chemical innovations.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This concentration means the company's legal team interacts with a single segment of the patent office. Such a structure allows for an understanding of the specific examiner's requirements and the art unit's internal trends without the complexity of multiple departments.
KIM, SUN U is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. Because there is only 1 pending office action in total, this examiner is responsible for the entire active workload. The outcome of the company's current prosecution depends on the interactions with this individual.
Practitioners managing this portfolio can prioritize a relationship within a single art unit. The presence of 1 distinct examiner for 1 pending office action ensures a direct relationship between the examiner and the active workload. This consistency may lead to more predictable prosecution timelines compared to portfolios distributed across multiple examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SUN U | 1 | 78.2% | +11.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043504 | TRANSFER SETS WITH FILTERS, INCLUDING TRANSFER SETS FOR PERITONEAL DIALYSIS SYSTEMS, AND ASSOCIATED SYSTEMS, DEVICES, AND METHODS | KIM, SUN U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043504 | TRANSFER SETS WITH FILTERS, INCLUDING TRANSFER SETS FOR PERITONEAL DIALYSIS SYSTEMS, AND ASSOCIATED SYSTEMS, DEVICES, AND METHODS | KIM, SUN U | — |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18043504 | TRANSFER SETS WITH FILTERS, INCLUDING TRANSFER SETS FOR PERITONEAL DIALYSIS SYSTEMS, AND ASSOCIATED SYSTEMS, DEVICES, AND METHODS | KIM, SUN U | 1777 | §102§103 | Non-Final OA | — | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial